RxDoctor Payments Data

Jenifer Zhai, MD

Neurology · Springfield, MONPI 1144388745

Payments from drug & device makers

$48,085in general payments, 2019–2025

Across 73 payments — averaging $658.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$39K
  • Biogen$6K
  • Argenx US, Inc.$2K
  • Medtronic$532
  • TG Therapeutics, Inc.$123
  • AbbVie$109
  • plus $413 from 6 others

What the payments were for

  • Consulting fees$4,61811%
  • Speaking & faculty fees$32,54377%
  • Travel & lodging$2,5086%
  • Food & beverage$2,5466%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,085 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$350,000
Medicare patients
715
Services billed
31,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone25$657,843
FingolimodFingolimod Hcl57$245,676
TecfideraDimethyl Fumarate25$226,368
CopaxoneGlatiramer Acetate26$164,336
Teriflunomide81$153,572
AubagioTeriflunomide16$148,184
Aimovig AutoinjectorErenumab-Aooe165$134,952
ZeposiaOzanimod Hydrochloride11$115,265
Glatiramer Acetate33$88,847
QuliptaAtogepant43$51,126
BriviactBrivaracetam29$48,792
Emgality PenGalcanezumab-Gnlm54$45,336
VimpatLacosamide23$39,564
Lacosamide291$33,529
GlatopaGlatiramer Acetate12$31,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys, Tecfidera$5,969$884,21050 claims
SanofiAubagio$39,173$148,18416 claims
AbbVieQulipta, Ubrelvy, Namzaric$109$82,19471 claims
PfizerNurtec Odt$18$21,77216 claims
Lilly USA, LLCReyvow$84$16,75323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 381 neurology providers in Missouri.

Other neurology in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →